EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was founded in 1987, formerly known as pSivida Corp., changed to its current name in March 2018, headquartered in Watertown, Massachusetts, USA, with 22 full-time employees, is a specialty biopharmaceutical company , Engaged in the development and commercialization of medical products related to ophthalmic indications with high medical needs to help improve the lives of patients with eye diseases.
EyePoint Pharmaceuticals (EYPT):
EyePoint Pharmaceuticals has developed three FDA-approved ophthalmic sustained-release treatment methods, including: DEXYCU (dexamethasone intraocular suspension), which is used as a single intraocular dose for postoperative inflammation at the end of eye surgery; ILUVIEN (fluocinolone acetonide) Intravitreal implant), a microimplant for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
EyePoint Pharmaceutical’s main product candidate is Duraset (fluocinolone acetonide intravitreal implant), a miniature implant used to treat non-infectious uveitis that affects the posterior segment of the eye.
In addition, EyePoint Pharmaceuticals’ pre-clinical development plan focuses on using its core Duraset platform technology to provide drugs for the treatment of wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.
EyePoint Pharmaceuticals, Inc. signed a license agreement for Retisert products with Bausch and Lomb; signed a license agreement with Alimera for the intuitive application of ILUVIEN equipment; and signed a cooperation agreement with Pfizer for the supply of latanoprost Duraset equipment.